CDC logoSafer Healthier People  CDC HomeCDC SearchCDC Health Topics A-Z
NIOSH - National Institute for Occupational Safety and Health

NIOSH Docket Number 105:

Hazardous Drugs

 

A public meeting was held on August 28, 2007, in Washington, DC, to discuss and obtain comments on the draft document, “NIOSH Hazardous Drugs List Update.”

The free Adobe Acrobat Reader is needed to view these files. get acrobat reader


Pre-meeting Information
Notice of request for public to submit comments and attend public meeting; 72 FR 33507; 6/18/07 (1 page, 1,290kb)
List of new FDA drugs and warnings fitting NIOSH criteria for hazardous drugs; 2006 (3 pages, 2,480kb)
NIOSH Alert, “Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings,” DHHS (NIOSH) Publication No. 2004-105 (56 pages, 15,910kb)
List of new FDA drugs and warnings not fitting NIOSH criteria for hazardous drugs, 2006 (5 pages, 3,670kb)
Meeting Information
Presentation by Reed/Connor (NIOSH) at the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07 (16 pages, 2,620kb)
List of attendees – 8/27/07 (2 pages, 44kb)
Post-Meeting Information
Transcript of the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07; Part 1 (121 pages, 22,780kb)
Transcript of the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07; Part 2 (52 pages, 20,830kb)
Submission to the docket from private person – 6/14/07 (8 pages, 279kb)
Submission to the docket from private person – 6/19/07 (1 page,17kb)
Submission to the docket from private person – 6/19/07 (1 page, 23kb)
Submission to the docket from private person – 6/19/07 (9 pages, 295kb)
Submission to the docket from Thies (St. Luke’s Hospital) – 6/22/07 (8 pages, 205kb)
Submission to the docket from Olson (GlaxoSmithKline) – 8/1/07 (1 page, 196kb)
Submission to the docket from Fabbro (BC Cancer Agency) – 8/24/07 (2 pages, 535kb)
Submission to the docket from Werner (The National Home Infusion Association) – 8/27/07 (3 pages, 675kb)
Submission to the docket from Schmidt (Western Missouri Mental Health Center) – 8/28/07 (8 pages, 1,490kb)
Submission to the docket from private person  – 9/6/07 (8 pages, 4,360kb)
Submission to the docket from private person – 9/8/07 (8 pages, 177kb)
Submission to the docket from Swyres (Barnes-Jewish Hospital) – 9/10/07 (5 pages, 2,690kb)
Submission to the docket from private person – 9/11/07 (8 pages, 151kb)
Submission to the docket from private person – 9/12/07 (1 page, 20kb)
Submission to the docket from Suter (Novartis Pharma AG) – 9/17/07 (5 pages, 984kb)
Submission to the docket from Wylie (Wyeth) – 9/18/07 (3 pages, 1,580kb)
Submission to the docket from Murano (Genentech, Inc) – 9/18/07 (19 pages, 9,420kb)
Submission to the docket from Oliver (AstraZeneca) – 9/19/07 (9 pages, 5,090kb)
Submission to the docket from Hung (Mayo Clinic) – 9/19/07 (32 pages, 12,620kb)
Submission to the docket from Reilly/Coffey (American Society of Health-System Pharmacists) – 9/20/07 (17 pages, 4,760kb)
Submission to the docket from Collura (Clarian Health) – 9/20/07 (8 pages, 1,690kb)
Submission to the docket from Roman (Boehringer Ingelheim Pharmaceuticals, Inc) – 9/20/07 (9 pages, 6,420kb)
Submission to the docket from Roman (Ben Venue Laboratories) – 9/20/07 (5 pages, 216kb)
Submission to the docket from Schwartz (Pfizer Inc) – 9/20/07 (6 pages, 3,090kb)
Submission to the docket from Sigler (Kaiser Permanente) – 9/20/07 (6 pages, 153kb)
Submission to the docket from Treanor (BioPharma EHS Forum) – 9/20/07 (10 pages, 2,730kb)
Submission to the docket from White (Pharmaceutical Research and Manufacturers of America) – 9/20/07 (8 pages, 4,730kb)
Submission to the docket from Bough/Gans (American Pharmacists Association) – 9/20/07 (5 pages, 2,870kb)
Submission to the docket from Stewart (Kaiser Permanente) – 9/21/07 (6 pages, 186kb)
Submission to the docket from Cadsap (Tercica) – 9/26/07 (3 pages, 2,100kb)
Submission to the docket from McHugh (Gilead Sciences, Inc) – 9/26/07 (43 pages, 29,120kb)
Submission to the docket from Olson (GlaxoSmithKline) – 9/20/07 (11 pages, 2,340kb)
Submission to the docket from McGrath (Bristol-Myers Squibb Company) – 9/28/07 (6 pages, 4,830kb)
Submission to the docket from Olson (GlaxoSmithKline) – 12/12/07 (13 pages, 420kb)
Submission to the docket from Cormack (Sucampo Pharmaceuticals) – 1/22/08 (10 pages, 1,960kb)

 

The NIOSH Docket